Study of Tremelimumab in Patients With Advanced Solid Tumors

Status Completed

Clinical Trial Summary

A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients with Advanced Solid Tumors

Clinical Trial Description

This is an open-label, multi-center study to determine the efficacy and safety of tremelimumab in the treatment of different cohorts of patients with selected advanced solid tumors. If eligible and at the discretion of the Investigator, after confirmed disease progression on tremelimumab monotherapy or during follow-up, patients will have the option of being sequenced to MEDI4736 (MedImmune 4736) monotherapy or MEDI4736 + tremelimumab combination therapy, for up to 12 months or until disease progression, whichever comes sooner. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02527434
Study type	Interventional
Source	AstraZeneca
Contact
Status	Completed
Phase	Phase 2
Start date	November 2, 2015
Completion date	March 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05209074` - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma	Phase 1
Recruiting	`NCT04927780` - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer	Phase 3
Recruiting	`NCT04969731` - Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer	Phase 3
Recruiting	`NCT05048524` - Peri-operative SLOG for Localized Pancreatic Cancer	Phase 2
Terminated	`NCT04042480` - A Study of SGN-CD228A in Advanced Solid Tumors	Phase 1
Completed	`NCT03257150` - A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer	N/A
Terminated	`NCT04400903` - Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
Active, not recruiting	`NCT05462717` - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors	Phase 1
Active, not recruiting	`NCT03267316` - A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors	Phase 1/Phase 2
Recruiting	`NCT04970056` - Pancreatic Cancer Early Detection Consortium
Terminated	`NCT04046887` - Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC)	Phase 1
Recruiting	`NCT05964621` - Venous Thromboembolism in Primary Pancreatic Tumour Resection
Active, not recruiting	`NCT04827953` - Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer	Phase 1/Phase 2
Recruiting	`NCT04291651` - UCSF PANC Cyst Registry
Recruiting	`NCT05977322` - A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.	Phase 1
Recruiting	`NCT05692596` - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Active, not recruiting	`NCT04862260` - Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma	Early Phase 1
Active, not recruiting	`NCT04853017` - A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors	Phase 1
Completed	`NCT03770117` - Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease
Completed	`NCT02259114` - A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)	Phase 1